177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

被引：22

作者：

Assadi, Majid ^{[1
]}

Pirayesh, Elahe ^{[2
]}

Rekabpour, Seyed Javad ^{[3
]}

Zohrabi, Farshad ^{[4
]}

Jafari, Esmail ^{[1
]}

Nabipour, Iraj ^{[5
]}

Esmaili, Abdolhamid ^{[6
]}

Amini, Abdullatif ^{[7
]}

Ahmadzadehfar, Hojjat ^{[8
]}

机构：

[1] Bushehr Univ Med Sci, Bushehr Med Univ Hosp, Persian Gulf Nucl Med Res Ctr, Dept Mol Imaging & Radionuclide Therapy,Fac Med, Bushehr, Iran

[2] Shahid Beheshti Univ Med Sci, Shohada & Tajrish Med Ctr, Dept Nucl Med, Tehran, Iran

[3] Bushehr Med Univ Hosp, Dept Oncol, Bushehr, Iran

[4] Bushehr Med Univ Hosp, Dept Urol, Bushehr, Iran

[5] Bushehr Med Univ Hosp, Dept Internal Med, Div Endocrinol, Bushehr, Iran

[6] Bushehr Med Univ Hosp, Dept Pathol, Bushehr, Iran

[7] Bushehr Univ Med Sci, Dept Cardiol, Bushehr Heart Med Ctr, Bushehr, Iran

[8] Univ Hosp Bonn, Dept Nucl Med, Bonn, Germany

来源：

CLINICAL NUCLEAR MEDICINE | 2019年 / 44卷 / 12期

关键词：

prostate cancer; neuroendocrine differentiation; Lu-177-PSMA; Lu-177-DOTATATE; GA-68-PSMA; MEDICINE;

D O I：

10.1097/RLU.0000000000002824

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

We presented a promising result of radionuclide therapy using Lu-177-PSMA and Lu-177-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-resistant prostate cancer may pave the way toward implementation of novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer.

引用

页码：978 / 980

页数：3

共 8 条

[1] 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor [J].